Cardiovascular risk in diabetes mellitus and hypertension in Spain. The CORONARIA study;Riesgo cardiovascular en diabetes mellitus e hipertensión arterial en España. Estudio CORONARIA

Medicina Clinica

Volumn 127, Issue 4, 2006, Pages 126-132

  Cosín Aguilar, Juan ^a   Rodríguez Padial, Luis ^b   Hernándiz Martínez, Amparo ^a   Arístegui Urrestarazu, Rosa ^c   Masramón Morell, Xavier ^d   Armada Peláez, Beatriz ^c   Aguilar Llopis, Amparo ^a   Zamorano Gómez, José L ^e  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c PFIZER INC   (United States)

^d Euroclin   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Amlodipine; Cardiovascular risk; Diabetes mellitus; Systemic hypertension; Type 2 diabetes

Indexed keywords

AMLODIPINE;

ADULT; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RISK FACTOR; SPAIN;

EID: 33747013360     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13090381     Document Type: Article

References (47)

1. Banegas JR, Ruilope LM. Epidemia de enfermedades metabólicas. Una llamada de atención. Med Clin (Barc). 2003;120:99-100.
2. King H, Aubert RE, Herman WH. Global burden of diabetes 1995-2025. Prevalence, numerical estimates and projections. Diabetes Care. 1998;21:1414-31.
3. Encuesta Nacional de Salud 2001. Ministerio de Sanidad y Consumo. Instituto de Información Sanitaria. 2003;7.
4. Masiá R, Sala J, Rohlfs I, Piulats R, Manresa JM, Marrugat J; Investigadores del estudio REGICOR. Prevalencia de diabetes mellitus en la provincia de Gerona, España: el estudio REGICOR. Rev Esp Cardiol. 2004;57:261-4.
5. Haffner SM, Lehto S, Ronnemas T, Pyorala K, Laskso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-34.
6. Kanters SD, Banda JD, Stolk RP, Algra A. Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. Vasc Med. 1999;4:67-75.
7. Hu FB. The impact of diabetes and prediabetes on risk of cardiovascular disease and mortality. Drugs Today (Barc). 2002;38:769-75.
8. Evans JMM, Wang J, Morris D. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had a myocardial infarction: cross sectional and cohort studies. BMJ. 2002;324:1-5.
9. Cho E, Rimm EB, Stampfer MJ. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol. 2002;40:954-60.
10. Lee C, Folsom A, Pankow J. Cardiovascular events in diabetics and nondiabetics adults with or without history of myocardial infarction. Circulation. 2004;109:855-60.
11. Clark CM, Perry RC. Type 2 diabetes and macrovascular disease. Epidemiology and etiology. Am Heart J. 1999;138:330-3.
12. Ryden L, Malmberg K. Reducing the impact of diabetic hearts's increases vulnerability to cardiovascular disease. Dialogues in Cardiovascular Medicine. 2000;5:5-22.
13. Gaede P, Vedel P, Larsen N, Jensen GVH, Praving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383-93.
14. Baena JM, Álvarez Pérez B, Piñol P, Martín Peñacoba R, Nicolau M, Altes A. Asociación entre agrupación (clustering) de factores de riesgo cardiovascular y el riesgo de enfermedad cardiovascular. Rev Esp Salud Pública. 2002;76:7-15.
15. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 38. BMJ. 1998;317:703-13.
16. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003;107:753-6.
17. Guidelines subcommittee WHO. 1999 World Health Organization. International Society of Hypertension Guidelines for the management of hypertension. J Hypertens. 1999;17:151-83.
18. Wilson PWF, D'Agostina RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factors categories. Circulation. 1998;97:1837-47.
19. Cosín J, Rodríguez L, Zamorano JL, Arístegui R, Armada B, Hernándiz A, et al. Diferencias de riesgo coronario en pacientes hipertensos de las comunidades autónomas. Estudio CORONARIA. Rev Clin Esp. 2004;12:614-25.
20. National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
21. Marrugat J, Solanas P, D'Agostino R, Sullivan L, Ordovás J, Cordón F, et al. Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada. Rev Esp Cardiol. 2003;56:253-61.
22. Lozano JV, Redón J, Cea-Calvo L, Fernández C, Navarro J, Bonet A, et al. Evaluación de un primer ictus en la población hipertensa española en atencióbn primaria. Estudio ERIC-HTA. Med Clin (Barc). 2005;125:247-51.
23. Alexander CM, Landsman PB, Teutsch SM. Diabetes mellitus, impared fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol. 2000;86:897-902.
24. Khot UN, Khot MB, Bajzer CT, Sapp Sk, Oman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898-904.
25. Duarte R, Castela S, Reis RP, Correia MJ, Ramos A, Pereira AP, et al. Acute coronary sindrome in a diabetic population-risk factors and clinical and angiographic characteristics. Rev Port Cardiol. 2003;22:1077-88.
26. Jonsdottir LS, Sigfusson N, Gudnason V, Sigvaldason H, Thorgeirsson G. Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? J Cardiovasc Risk. 2002;9:67-76.
27. Natarajan S, Liao Y, Cao G, Lipsitz SR, McGee DL. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch Intern Med. 2003;163:1735-40.
28. Lehto S, Ronnemaa TP, Pyorala K, Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type II diabetes. Diabetologia. 2000;43:148-55.
29. A joint editorial statement by the American Diabetes Association; the National Heart, Lung and Blood Institute; the Juvenile Diabetes Foundation International; the National Institute of Diabetes and Digestive and Kidney Diseases; and the American Heart Association. Diabetes mellitus: a mayor risk factor for cardiovascular disease. Circulation. 1999;100:1132-3.
30. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 2000;23:854-64.
31. Wood D, De Backer G, Gaergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies on Coronary prevention. Eur Heart J. 1998;19:1434-503.
32. Heart Protection Collaborative Group. NRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individual: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
33. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al, on behalf of CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004;364:685-96.
34. Colhum HM, Dong W, Barakat MT, Mather HM, Poulter NR. The scope for cardiovascular disease risk factor intervention among people with diabetes mellitus in England: a population-based analysis from the Health Surveys for England 1991-1994. Diabet Med. 1999;16:35-40.
35. Bo S, Caballo-Perin P, Gentile L. Prevalence of patients reaching the targets of good control in normal clinical practice. Diabetes Care. 1999;22:2092.
36. Rodríguez Padial L, Maicas Bellido C, Alcalá López J, Velázquez Martín M, Gil Polo B. Escasa aplicación de las medidas de prevención en los pacientes con diabetes mellitus tipo 2 y enfermedad arterial coronaria en España. Estudio DIETRIC. Rev Clin Esp. 2005;205:14-8.
37. De la Peña A, Suárez C, Cuende I, Muñoz M, Garré J, Camafort M, et al. Control integral de los factores de riesgo en pacientes de alto y muy alto riesgo cardiovascular en España. Estudio CI-FARC. Med Clin (Barc). 2005;124:44-9.
38. Lloyd-Jones DM, Wilson PW, Larson MG, Beiser A, Leip EP, D'Agostino RB, et al. Framingham risk score and prediction of lifetime risk for coronary heart disease. Am J Cardiol. 2004;94:20-4.
39. Thomseen TF, McGee D, Davidsen M, Jorgensen T. Across-validation of risk scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol. 2002;31:817-22.
40. De Visser CL, Bilo HJ, Thomsen TF, Gronier KH, Meyboom-de Jong B. Prediction of coronary heart disease: a comparison between the Copenhagen risk score and the Framingham risk score applied to a Dutch population. J Intern Med. 2003;253:553-62.
41. Wihelmsen L, Wedel H, Conroy R, Fitzgerald T. The Swedish Score chart for cardiovascular risk. Better possibilities for prevention of cardiovascular diseases. Lakartdningen. 2004;13:1798-801.
42. Averina M, Nilssen O, Brenn T, Brox J, Kalinin AG, Arkhipovsky VL. High cardiovascular mortality in Russia cannot be explained by the classical risk factors. The Arkhangelsk Study 2000. Eur J Epidemiol. 2003;18:871-8.
43. Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, et al. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ. 2003;327:1267.
44. Aranceta J, Pérez Rodrigo C, Foz Sala M, Mantilla T, Serra Majem L, Moreno B, et al. Grupo colaborativo para el estudio DORICA fase 2. Tablas de riesgo coronario adaptadas a la población española: el estudio DORICA. Med Clin (Barc). 2004;123:686-91.
45. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003.
46. Mostaza JM, Vicente I, Taboada M, Laguna F, Echaniz A, García-Iglesias F, et al. La aplicación de las tablas del SCORE a varones de edad avanzada triplica el número de sujetos clasificados de alto riesgo en comparación con la función de Framingham. Med Clin (Barc). 2005;124:487-90.
47. Cosín J, Hernándiz A, Rodríguez L, Zamorano JL, Arístegui R, Armada B, et al. Valoración del riesgo cardiovascular en grupos de población. Comparación de los sistemas de SCORE y Framingham en pacientes hipertensos. Rev Clin Esp. 2006;206:182-7.